Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib

Saved in:
Bibliographic Details
Published inLeukemia & lymphoma Vol. 58; no. 2; pp. 498 - 500
Main Authors Goldschmidt, Neta, Rund, Deborah
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.02.2017
Subjects
Aged
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biomarkers
Biopsy
Blood Cell Count
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - complications
Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
Pyrazoles - adverse effects
Pyrazoles - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Red-Cell Aplasia, Pure - diagnosis
Red-Cell Aplasia, Pure - etiology
Treatment Outcome
Online AccessGet full text

Cover

More Information
ISSN:1042-8194
1029-2403
DOI:10.1080/10428194.2016.1182163